A 38-year-old man with a history of intravenous drug use presents with jaundice, fatigue, and right upper quadrant pain for 2 weeks. He reports a tattoo done 6 months ago. Laboratory findings show ALT 3200 IU/L, AST 2800 IU/L, total bilirubin 9.5 mg/dL, INR 1.3, albumin 3.2 g/dL, and anti-HCV antibody positive. HCV RNA (quantitative) is 850,000 IU/mL. What is the most appropriate next step in management?

Question

Accepted Answer

C. Admit for supportive care, monitor INR and synthetic function; defer antiviral therapy until acute phase resolves. ## Clinical Context
This patient presents with **acute hepatitis C** — evidenced by recent high-risk exposures (IV drug use, tattoo 6 months ago), markedly elevated transaminases (ALT 3200, AST 2800), jaundice, and a positive anti-HCV antibody with detectable HCV RNA. The key management question is whether to start DAA therapy immediately or to observe first.

## Management of Acute Hepatitis C

**Key Point:** In **acute HCV infection**, current AASLD/IDSA guidelines recommend a period of **watchful waiting (8–12 weeks)** before initiating antiviral therapy, because **15–45% of patients spontaneously clear the virus** during this window. Premature treatment would expose a significant proportion of patients to unnecessary medication.

### Why Supportive Care with Deferred Antiviral Therapy Is the Correct Next Step

**High-Yield:** The standard approach in acute HCV (AASLD 2020, Harrison's Principles of Internal Medicine):
1. **Admit/monitor** for hepatic synthetic function (INR, albumin, bilirubin trends)
2. **Defer DAA therapy** for 8–12 weeks to allow spontaneous clearance
3. **Repeat HCV RNA** at 8–12 weeks — if still detectable, initiate DAA therapy
4. **Supportive care** (hydration, avoid hepatotoxins, rest) during the acute phase

**Clinical Pearl:** Spontaneous clearance is more likely in symptomatic patients (jaundice is a favorable sign), younger patients, females, and those with IL28B CC genotype. This patient's symptomatic presentation (jaundice) actually increases the probability of spontaneous clearance, making watchful waiting even more appropriate.

### Why INR 1.3 and Albumin 3.2 Do Not Change This Decision
These values reflect **acute hepatic inflammation**, not chronic decompensation. They are expected in severe acute hepatitis and are not contraindications to watchful waiting. They do, however, warrant **inpatient monitoring** to detect progression to acute liver failure.

## Why Each Distractor Is Wrong

| Option | Reason |
| --- | --- |
| **Immediate DAA therapy (Option A)** | Premature in acute HCV. Guidelines recommend waiting 8–12 weeks for possible spontaneous clearance before committing to antiviral therapy. Immediate treatment is appropriate only in **chronic** HCV or if the patient fails to clear spontaneously. |
| **Liver biopsy before therapy (Option B)** | Biopsy is **not indicated** in acute HCV management. Fibrosis staging does not alter the decision to observe first. Additionally, biopsy carries bleeding risk with INR 1.3. |
| **Interferon-alpha + ribavirin (Option D)** | This regimen is **obsolete**. Interferon-based therapy has been replaced by DAAs due to superior efficacy (>95% SVR) and tolerability. Interferon is also relatively contraindicated in acute hepatitis with coagulopathy. |

## Monitoring During Watchful Waiting

- **Repeat HCV RNA at 4 and 12 weeks** — if undetectable, spontaneous clearance confirmed
- **Monitor INR, bilirubin, albumin** — watch for progression to acute liver failure
- **Avoid hepatotoxins** (alcohol, NSAIDs, acetaminophen in high doses)
- **Screen for HBV and HIV** co-infection

**Mnemonic: WAIT in Acute HCV**
- **W** — Watch for spontaneous clearance (8–12 weeks)
- **A** — Admit if severe (monitor synthetic function)
- **I** — Interferon is obsolete
- **T** — Treat with DAAs only if HCV RNA persists at 12 weeks

*Reference: AASLD/IDSA HCV Guidance 2020; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Viral Hepatitis.*

Answer

A. Perform liver biopsy to assess fibrosis stage before initiating antiviral therapy

Answer

B. Initiate interferon-alpha and ribavirin combination therapy as first-line treatment

Answer

D. Start direct-acting antiviral (DAA) therapy immediately after confirming HCV RNA positivity

Option	Reason
Immediate DAA therapy (Option A)	Premature in acute HCV. Guidelines recommend waiting 8–12 weeks for possible spontaneous clearance before committing to antiviral therapy. Immediate treatment is appropriate only in chronic HCV or if the patient fails to clear spontaneously.
Liver biopsy before therapy (Option B)	Biopsy is not indicated in acute HCV management. Fibrosis staging does not alter the decision to observe first. Additionally, biopsy carries bleeding risk with INR 1.3.
Interferon-alpha + ribavirin (Option D)	This regimen is obsolete. Interferon-based therapy has been replaced by DAAs due to superior efficacy (>95% SVR) and tolerability. Interferon is also relatively contraindicated in acute hepatitis with coagulopathy.

Explanation

Clinical Context

Management of Acute Hepatitis C

Why Supportive Care with Deferred Antiviral Therapy Is the Correct Next Step

Why INR 1.3 and Albumin 3.2 Do Not Change This Decision

Why Each Distractor Is Wrong

Monitoring During Watchful Waiting

Practice similar questions

Join our NEET PG community